화이자 임상시험
-
CMC-544 in Relapsed Refractory Acute Lymphoblastic Leukemia (ALL)
-
Avelumab in Patients With MSS, MSI-H and POLE-mutated Recurrent or Persistent Endometrial Cancer and of Avelum
-
Fractionated Gemtuzumab Ozogamicin Followed by Non-engraftment Donor Leukocyte Infusions for Relapsed/Refracto
-
A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advan
-
Study to Evaluate the Safety and Efficacy of PF-06939926 for the Treatment of Duchenne Muscular Dystrophy
-
A Phase II Trial of Avelumab in Patients With Recurrent or Progressive Osteosarcoma
-
Study Evaluating 13-valent Pneumococcal Conjugate Vaccine (13vPnC) in Healthy Children Aged 15 Months to 17 Ye
-
The AVIATOR Study: Trastuzumab and Vinorelbine With Avelumab OR Avelumab & Utomilumab in Advanced HER2+ Breast
-
A Study to Evaluate the Efficacy and Safety of PF-06480605 in Adults With Moderate to Severe Ulcerative Coliti
-
CPX-351 and Glasdegib for Newly Diagnosed Acute Myelogenous Leukemia With MDS Related Changes or Therapy-relat
-
Encorafenib, Binimetinib and Cetuximab in Subjects With Previously Untreated BRAF-mutant ColoRectal Cancer
-
A Study to Learn About the Study Medicine PF-07220060 Together With Letrozole Compared to Letrozole Alone in W
-
Ritlecitinib for Cicatricial Alopecia
-
COcoa Supplement and Multivitamin Outcomes Study
-
Safety and Efficacy Study of Enzalutamide Plus Leuprolide in Patients With Nonmetastatic Prostate Cancer (EMBA
기업별 임상
화이자머크(MSD)로슈노바티스아스트라제네카존슨앤드존슨(얀센)BMS사노피GSK일라이 릴리애브비암젠바이엘베링거인겔하임노보 노디스크다케다길리어드모더나바이오엔테크리제네론버텍스바이오젠다이이찌산쿄아스텔라스에자이오츠카세르비에인사이트셀트리온삼성바이오에피스한미약품유한양행